Parmaceutical compositions comprising selective imidazoline receptor
agonists combined with angiotensin II receptor blockers, particularly,
pharmaceutical compositions comprising Moxonidine and Eprosartan
mesylate, as well as the use of such compositions for the treatment of
hypertension, especially in hypertensive patients suffering from type II
diabetes or susceptible to developing type II diabetes.
